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Abstract Vasohibin-1 is an intrinsic inhibitor of angiogenesis
induced by VEGF-A. However, there little is known about the
relationship between Vasohibin-1 expression, angiogenesis,
and tumor-associated macrophages (TAMs). Vasohibin-1 ex-
pression, VEGF-A expression, microvessel density (MVD)
marked with CD34, and density of cells marked with CD68
were measured in 111 paraffin-embedded tissues of gastric
cancer by immunohistochemistry. The length of tube forming
structures of endothelial cells and mobility rate of gastric can-
cer cells in Matrigel were tested by three-dimensional live cell
imaging system. The effect of TAMs on the tumor growth,
MVD, and Vasohibin-1 expression was measured by nude
mice tumor genesis assay in vivo. We found that high
Vasohibin-1 protein expression correlated significantly with
worse TNM stage (P=0.002), metastatic lymph node (P=
0.014), distant metastasis (P=0.022), overall survival
(P<0.001), and progression-free survival (P<0.001) com-
pared to those with low Vasohibin-1 expression. Vasohibin-1
protein expression had statistical correlation with the MVD
(r=0.860, P<0.001), density of CD68+ cells (r=0.882,
P<0.001), and VEGF-A expression (r=0.719, P<0.001) in
the gastric cancer tissues. Decreasing Vasohibin-1 expression
with siRNA increased the length of tube forming structures of
endothelial cells in co-culture with endothelial cells (EA-
hy923), macrophages, and gastric cancers (Hs746T). Tumor
volume (P=0.001), Vasohibin-1 (P<0.001), and VEGF-A
(P<0.001) expression in mice inoculated with AGS and
THP (10:1) was significantly higher than that with AGS alone
(P=0.001). Vasohibin-1 protein expression had statistical cor-
relation with VEGF expression (r=0.786, P<0.001) and
MVD (r=0.496, P=0.014) in gastric xenografted tumor.
Therefore, Vasohibin-1 might be a potential marker of worse
prognosis and therapeutic target in gastric cancer. Vasohibin-1
might play an important role in the process of angiogenesis
regulated by TAMs.
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Introduction
Angiogenesis, also called neovascularization, is a fundamen-
tal process of blood vessel growth and a hallmark of cancer
development [1]. The angiogenesis is the balance of activities
of angiogenesis stimulators and inhibitors [2, 3]; Vasohibin-1
was originally identified as an endothelium-derived VEGF-
inducible angiogenesis inhibitor that acts in a negative feed-
back manner [4]. The expression of Vasohibin-1 has been
shown in endothelial cells in both physiological and patholog-
ical conditions including cancer associated with angiogenesis
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[5–7]. Actually, Vasohibin-1 is not only expressed in endothe-
lial cells but also other cell types, like hematopoietic cells [8]
and cancer cells [9]. In 2012, we firstly reported the
Vasohibin-1 could express in gastric cancer cells and could
be regulated by tumor-associated macrophages (TAMs) [10].
TAMs has been shown to play a critical role in contributing to
tumor angiogenesis by regulating the balance of
proangiogenic and antiangiogenic factors [11–13]. However,
there is little known about the relationship between Vasohibin-
1 expression, angiogenesis, and TAMs by now, except of our
previous report.
In this study, we investigated the Vasohibin-1, VEGF-A
expression, microvessel density (MVD) labeled by CD34,
and density of TAMs labeled by CD68 by immunohistochem-
istry in gastric cancer tissues. The relationship between the
Vasohibin-1 expression, MVD, and density of TAMs was an-
alyzed. The effect of Vasohibin-1 expression and TAMs on the
angiogenesis was analyzed by measuring length of tube
forming structures of endothelial cells in vitro under three-
dimensional (3D) live cell imaging system and nude mouse
tumorigenicity assay in vivo. We hope this study might throw
more information about the regulation of Vasohibin-1 expres-
sion and angiogenesis induced by TAMs in gastric cancer.
Materials and methods
Samples
Samples of the gastric carcinoma tissue were obtained from
111 consecutive patients with gastric cancer who had under-
g o n e t umo r r e s e c t i o n a t t h e D e p a r tm e n t o f
Gastroenterological Surgery at Peking University People’s
Hospital between January 2005 and July 2006. Informed con-
sent was obtained from each patient who participated the
study. The specimens were fixed in formalin in 5 min after
surgical resection, and then embedded with paraffin until
used. Clinicopathological data are shown in Table 1. Cancer
staging relies on the 7th TNM system designed by the
American Joint Committee on Cancer (Supplementary
Table 1). The study obtained the approval of the Institutional
Review Board and through the ethic committee in the locality.
Immunohistochemistry
Envision method was used to perform immunohistochemical
staining for Vasohibin-1, VEGF-A, CD34, and CD68 in gastric
cancer tissues. Specimens had been fixed in 10 % formalin,
embedded in paraffin, cut into 4 μm thick sections, and placed
on the glue-coated glass slides. Sections were deparaffinized in
xylene and hydrated with graded alcohols and distilled water. To
retrieve the immunoreactivity, tissue sections were boiled in cit-
rate buffer (pH 6.0) for CD34 and VEGF-A in 10 mM EDTA
(pH 9.0) for Vasohibin-1 and CD68 for 20 min at above 95 °C.
Mouse polyclonal Vasohibin-1 antibody, mouse monoclonal
VEGF-A antibody, rabbit polyclonal CD34 antibody, and rabbit
monoclonal CD68 antibody were added to adjacent tissue sec-
tions, respectively, and incubated overnight at 4 °C. The primary
antibodies were used as follows: anti-human Vasohibin-1 poly-
clonal antibody (sc-365541, Santa Cruz Biotechnology, Europ)
and anti-CD34 (ab27448, Abcam, Cambridge, UK) both diluted
at 1:100, anti-CD68 (ab955, Abcam, Cambridge, UK) diluted at
1:200, anti-VEGF-A (ab105219, Abcam, Cambridge, UK) dilut-
ed at 1:50. Horseradish peroxidase conjugated second antibody
was added to the sections and incubated at room temperature for
20 min. DAB was used for the color reaction according to the
manufacturer’s instructions, and then the slides were counter-
stained with hematoxylin. The tissue sections were washed
with phosphate buffer solution (PBS) (0.01 M, pH 7.4)
between each step. Positive and negative controls were
simultaneously used to ensure the specificity and reli-
ability of staining. As a positive control, tissue sections
from endometrial carcinoma were used. Sections were
processed with 0.01 M PBS instead of the primary an-
tibody, which was used as negative control. The positive
result showed yellow or brown coloration in cytoplasm
and/or plasma membranes.
Immunohistochemical analysis
Two independent assessors unaware of the patient outcome
carried out this semiquantitative analysis. The average number
counted by the two investigators was used for subsequent
analysis. The degree of Vasohibin-1 and VEGF-A staining
was estimated by semiquantitative evaluation and categorized
by the extent and intensity of staining as follows [14]: The
extent of positive cells was estimated as 0=positive staining
cells 5 %, 1=positive staining cells in 6~25 %, 2=positive
staining cells in 26~50 %, 3=positive staining cells in 51~
75 %, and 4=positive staining cells >75 %. The intensity of
staining was scored as 0=achromatic, 1=light yellow, 2=yel-
low, and 3=brown. Combined staining score was used to
evaluate the results of staining. The extent of positive cells
was multiplied by the intensity of staining and scored as fol-
lows: (–)=0, (+)=1–4, (++)=5–8, and (+++)=9–12. Negative
(–) and weak (+) were categorized as low expression, and
moderate (++) and strong (+++) as high.
Microvessel density counting
Microvessels marked by CD34 were counted. The areas with
the greatest number of distinctly highlighted microvessels
were selected. Any cell clusters with CD34-positive signals
were regarded as a single countable microvessel, regardless of
whether the lumen was visible. Unstained lumina were con-
sidered artifacts, even if they contained blood or tumor cells.
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The results of MVD were expressed as the highest number of
capillaries and small venules identified within any single ×200
field (×20 objective and ×10 ocular, 0.785 mm2 per field) in
gastric cancer tissues [15] and ×400 (×40 objective and ×10
ocular, 0.785 mm2 per field) field in the xenografts of nude
mice, in accordance with an original method.
Density of CD68+ cells
A single pathologist, who was blinded to the clinical assess-
ments of each case, scored the cases by counting the number
of CD68+ cells (macrophage marker) in six independent fields
under a ×200 magnification. CD68+ cell counts were
expressed as the mean±standard deviation.
Isolation of monocytes and macrophages
Mononuclear cells were isolated form healthy subjects blood
with density gradient centrifugation (Ficol-Paque,
Amershamn, Uppsala, Sweden). The cells were washed with
PBS+10 % acid citrate dextrose (ACD) solution two times.
The cells were counted and 1.4×106 cells were placed on
Matrigel (Matrigel, BD Biosciences, San Jose, CA) covered
cover slip (Nalge Nunc International Corporation, Naperville,
German). The isolated cells were grown in serum-free medi-
um designed for macrophages (Macrophage serum-free medi-
um, Gibco, Paislay, UK) with granulocyte-macrophage colo-
ny-stimulating factor (GM-CSF, 10 ng/mL, Immuno Tools,
Oldenburg, Germany), antibiotics, and 5 % CO2 at 37 °C.
Monocytes adhered to the Matrigel overnight and differenti-
ated to macrophages due to GM-CSF. Monocytes were fully
differentiated into macrophages after 6 days and then used for
experiments. When co-cultured with cancer cells, macro-
phages developed into TAMs with special surface marker,
CD 206, CD14+ [16]. After co-culturing with gastric cancer
cells, the portion of CD 206+, CD14+ positive macrophages
reached more than 80 % measured with flow cytometry.
Cells culture
AGS cell line (CRL-1739) was purchased from ATCC
(American Type Culture Collection). The cells were cultured in
Ham’s F12K medium with 2 mM L-glutamine adjusted to con-
tain 1.5 g/L sodium bicarbonate, 10% fetal bovine serum (FBS),
Table 1 Correlation between
Vasohibin-1 expression and
clinicopathologic factors









Male 81 51 (63.0 %) 30 (37.0 %)
Female 30 16 (53.3 %) 14 (46.7 %)
Age 0.763
≤60 years 46 27 (58.7 %) 19 (41.3 %)




Poorly 57 35 (61.4 %) 22 (38.6 %)
Moderately 43 24 (55.8 %) 19 (44.2 %)




T1-T2 34 28 (82.4 %) 6 (17.6 %)
T3-T4 77 39 (50.6 %) 38 (49.4 %)
Lymph node status 0.014*
Negative 35 27 (77.1 %) 8 (22.9 %)
Positive 76 40 (52.6 %) 36 (47.4 %)
Distant metastasis 0.022*
Negative 94 61 (64.9 %) 33 (35.1 %)
Positive 17 6 (35.3 %) 11 (64.7 %)
TNM stage 0.002*
I-II 39 31 (79.5 %) 8 (20.5 %)
III-IV 72 36 (50 %) 36 (50 %)
*Significant at the p<0.05 level. Pearson’s Chi-Square test was used
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and antibiotics (100 μg/mL penicillin and 100 U/mL
streptomycin).
Hs 746T (HTB-135) cell line was purchased from ATCC.
Cells were cultured in Dulbecco’s modified Eagle’s medium
(DMEM) with 4 mM L-glutamine adjusted to contain 1.5 g/L
bicarbonate, 4.5 g/L glucose, 10 % FBS, and antibiotics
(100 μg/mL penicillin and 100 U/mL streptomycin).
EA.hy926 cell line was the human umbilical vein cell line
and purchased from ATCC. Cells were cultured in DMEM
with 10 % FBS and antibiotics (100 μg/mL penicillin and
100 U/mL streptomycin).
THP cell line derived from the monocytes from the human
perineal blood and purchased fromATCC. Cells were cultured
in RPMI-1640 medium, with 2-mercaptoethanol to a final
concentration of 0.05 mM added, 10 % FBS and antibiotics
(100 μg/mL penicillin and 100 U/mL streptomycin).
All cell lines were maintained at 37 °C in a humidified
atmosphere with 5 % CO2.
Invasion and migration assay (3D dynamic migration
imaging system)
Cells were grown on Matrigel-covered cover slip wells with
serum-free medium designed for macrophages. Gastric cancer
cells were grown either alone or with differentiated macrophages
and/or EA.hy926 cells on Matrigel under normal oxygenic con-
dition. siRNA transfection kit (sc-45064, Santa Cruz
Biotechnology, USA) was used to down regulate the
Vasohibin-1mRNAexpression. Gastric cancer cells were stained
with fluorescent dye (CellTracker green CMFDA, Invitrogen,
Eugene, OR) before imaging. During the invasion phase, the
cancer cells invaded in Matrigel were imaged by 3D dynamic
migration imaging system (Olympus A×70 Research System
microscope, Japan). The average migration speed was calculated
from the cells which could be tracked at least for 6 hours in one z-
plane (ImagePro Plus, Media Cybernetics, Bethesda, MD).
The length of tube forming structures of endothelial cells
in vitro
The endothelial cells were cultured in the Matrigel alone or with
FBS+EGF, or with macrophages, or with Hs 746Tcells, or with
macrophages+Hs 746T fetal bovine serum (5%, FBS) and EGF
(10 ng/mL) were used as a positive control to stimulate tube
formation. siRNA technique was used to decrease Vasohibin-1
expression (Santa Cruz Biotechnology) in cancer cells and non-
targeting (NT) siRNAwas used as negative control. The endo-
thelial cells were colored with fluorescent dye (CellTracker green
CMFDA, Invitrogen, Eugene, OR) before imaging. The move-
ment of cells in Matrigel was imaged by 3D dynamic migration
imaging system. We have manually searched for cell structures
extending two elongated cells in length and having two to three
cells side by side or over each other in the other direction along
the diameter of a tube to be formed. The length of the elongated
cells was measured manually, thereby analyzing length of possi-
ble tube forming structures. The analysis was done with
ImagePro 7.01.
In vivo tumor growth assay
BALB/c female nude mice (4 weeks old) were purchased from
Beijing Vital River Laboratories (China). These mice were main-
tained in a specific pathogen-free environment in the
Experimental Animal Center of Peking University People’s
Hospital. The animal experiments were approved and reviewed
by the Animal Research Committee of the Peking University
People’s Hospital. Care and handling of the animals were in
accordance with the guidelines for Institutional and Animal
Care and Use Committees.
Mice were randomly divided into four groups (AGS,
AGS+THP (5:1), AGS+THP (10:1), and AGS+THP
(20:1)) with six mice in each group. The concentration of
basic cell solution of AGS and THP was 2×107 cells/mL
and 4×106 cells/mL, respectively. The cells were mixed ac-
cording to the percentage above. Cell solution (0.2 mL) was
injected subcutaneously into mice. Tumor volumes were mea-
sured every 7 days and calculated according to the formula V=
0.5×L (length)×W2 (width). At 21 days after the cell inocula-
tion, mice were sacrificed and tumors were excised tomeasure
the volume and weight. The expression of Vasohibin-1,
VEGF-A, and CD34 was detected by immunohistochemistry.
Definition of overall survival and progression-free
survival
Overall survival (OS) was calculated from the time of surgery
to last follow-up or date of death. For patients who recurred or
metastasized, progression-free survival (PFS) was calculated
as the time from surgery to time of first recurrence; for those
that did not recur or metastasize, PFS was defined as the time
from surgery to last follow-up/death.
Results
Vasohibin-1 expression in the gastric cancer tissues and its
relationship with clinicopathological characteristics
and prognosis
Sixty-seven and 44 gastric cancer tissues showed low and
high expression of Vasohibin-1 protein, respectively. There
was no significant correlation between Vasohibin-1 protein
expressions and age, sex, and tumor differentiation. Tumors
with deeper depth of invasion had significantly higher
Vasohibin-1 protein expression than those with superficial in-
vasion (P=0.002). High Vasohibin-1 expression was detected
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more often in patients with metastatic lymph node and distant
metastasis (P=0.014, P=0.022, respectively). High
Vasohibin-1 protein expression correlated significantly with
worse TNM stage (P=0.002) (Table 1, Fig. 1).
Follow-up rate of gastric cancer patients is 96.4 % (107/111).
Patients with high Vasohibin-1 expression had significantly
worse OS and PFS compared with those with low Vasohibin-1
expression (mean OS time: 34.6 vs. 63.5 month, P<0.001; me-
dian PFS time: 33.7 vs. 62.9 month, P<0.001) (Fig. 2).
The correlation between the Vasohibin-1 and VEGF-A
protein expressions in the gastric cancer tissues
The tissues with VEGF-A low expression accounted for
85.1% (57/67) and 29.5% (13/44) in the gastric cancer tissues
with Vasohibin-1 low and high expression, respectively
(P<0.001) (Fig. 1). There was significant correlation between
Vasohibin-1 and VEGF-A protein expressions in the gastric
cancer tissues by the analysis of immunohistochemistry (r=
0.719, P<0.001) (Fig. 3).
The correlation between the Vasohibin-1 expression
and the MVD in the gastric cancer tissues
The meanMVD in the gastric cancer tissues with Vasohibin-1
low and high expression was 28.9±12.3 and 61.4±19.1,
which had statistical difference (P<0.001), respectively.
Immunohistochemistry showed that Vasohibin-1 protein ex-
pression had statistical correlation with theMVD in the gastric
cancer tissues (r=0.860, P<0.001) (Figs. 1 and 3).
The correlation between the Vasohibin-1 expression
and the density of CD68+ cells in gastric cancer tissues
There was a significant difference between the density of
CD68+ cells (macrophage marker) in the gastric cancer tissues
with Vasohibin-1 low and high expression (32.7±18.3 and
73.7±19.8, P<0.001). Significantly positive correlations were
found between Vasohibin-1 expression and the density of
CD68+ cells in the gastric tissues (r=0.882, P<0.001)
(Figs. 1 and 3)




expression: (a) Week (light
yellow), (b) positive (yellow), (c)
strong positive (brown). ×200;
VEGF expression: (d) week (light
yellow), (e) positive (yellow), (f)
strong positive (brown). ×200;
microvessels marked with CD34
(g, h, i ×200); CD68+ cells (j, k, l
×200)
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The effect of TAMs and Vasohibin-1 on the length of tube
forming structures of endothelial cells in Matrigel
The length of tube forming structures in Matrigel of the group
of EA.hy923 cells alone, EA.hy923+FBS+EGF, EA.hy923+
macrophages, EA.hy923+Hs746T cells, EA.hy923+macro-
p h a g e s + H s 7 4 6 T, EA . h y 9 2 3 + m a c r o p a h g e s +
Hs746TVasohibin-1 siRNA, and EA.hy923+macrophages+
Hs746T NT were 40.7±7.5, 65.5±8.6, 52.1±6.3, 42.0±4.9,
38.1±2.3, 61.4±3.1, and 38.6±3.0 μm, respectively. There
was statistical difference of tube length between the
EA.hy923 alone group and EA.hy923+macrophages group
(P<0.001). The tube length of EA.hy923+macrophages+Hs
746TVasohibin-1 siRNA group was significantly longer than
EA.hy923+macrophages+Hs 746T group (P<0.001) and NT
group (P<0.001) (Fig. 4).
The effect of TAMs and Vasohibin-1 on the invasion
of gastric cancer cells in the Matrigel
The mobility rate of Hs746Twith macrophages (5.1±0.0 μm
vs. 3.1±0.0 μm/h (without macrophages), P<0.001), with
EA.hy923 (8.4±0.1 μm vs. 3.1±0.0 μm/h, P<0.001) and
with macrophages+EA.hy923 (8.5±0.1 μm vs. 3.1±
0.0 μm/h, P<0.001) was significantly faster than that of
Hs746T alone in Matrigel.
Vasohibin-1 siRNA significantly increased the mobility of
Hs746T cells in above all groups (Hs 746T Vasohibin-1
siRNA vs. Hs746T: 3.6±0.1 μm vs. 3.1±0.0 μm/h, P=
0.001; Hs 746T Vasohibin-1 siRNA+macrophages vs.
Hs746T+macrophages: 6.2±0.1 μm vs. 5.1±0.0 μm/h,
P<0.001; Hs 746T Vasohibin-1 siRNA+EA.hy923 vs.
Hs746T+EA.hy923: 8.7±0.1 μm vs. 8.4±0.1 μm/h, P=
Fig. 2 Gastric cancer patients
with high Vasohibin-1 expression
in tumors show poor overall
survival (OS) and progression-
free survival (PFS). Vasohibin-1
expression was measured by
immunohistochemistry in tumors
of gastric cancer patients
Fig. 3 Correlation within Vasohibin-1, VEGF-A expression, microvessel density (MVD), and density of CD68+ cells in gastric cancer tissues analyzed
by immunohistochemistry
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0.018; Hs 746T Vasohibin-1 siRNA+macrophages+
EA.hy923 vs. Hs746T+macrophages+EA.hy923: 11.3±
0.1 μm vs. 8.5±0.0 μm/h, P<0.001).
The effect of TAMs on the tumor growth and angiogenesis
and the relationship with Vasohibin-1 expression in vivo
After 21 days, the tumor volume of mice inoculated with AGS
cells alone was 1551.1±213.8 mm3, whereas that injected with
AGS+THPmacrophages by the ratio of 5:1, 10:1, and 20:1 was
1881.9±128.2 mm3 (P=0.334), 2781.9±353.2 mm3 (P=0.001),
and 2333.2±189.9 mm3 (P=0.030), respectively (Fig. 5).
Compared to the AGS group (0.87±0.18 g), the tumor
weight was reduced by 6.9 % in the AGS+THP (5:1) group
(0.77±0.10 g, P=0.568), but that was increased by 8.0 and
23.0 % in the AGS+THP (10:1) group (1.14±0.10 g, P=
0.123) and AGS+THP (20:1) group (1.36±0.10 g, P=
0.010) (Fig. 5).
Both of Vasohibin-1 and VEGF-A expression scores in
AGS+THP (5:1) group (P<0.001, P=0.022), AGS+THP
(10:1) group (P<0.001, P<0.001), and AGS+THP (20:1) group
(P<0.001, P=0.001) were significantly higher than that of AGS
alone group. The Vasohibin-1 and VEGF-A expression scores in
AGS+THP (10:1) group were significantly higher than both of
AGS+THP (5:1) group (P<0.001, P=0.007) and AGS+THP
(20:1) group (P<0.001, P=0.001) (Fig. 5).
The mean MVD in the AGS+THP (10:1) group was sig-
nificantly higher than that of AGS alone group (P=0.030),
AGS+THP (5:1) group (P=0.001), but not AGS+THP
(20:1) group (P=0.111). The mean MVD in AGS+THP
(5:1) group was statistically lower than that of AGS alone
group (P=0.043) (Fig. 5).
Vasohibin-1 protein expression detected by immunohisto-
chemistry had statistical correlation with VEGF expression
(r=0.786, P<0.001) and MVD in the gastric xenografted tu-
mor (r=0.496, P=0.014) (Fig. 5).
Discussion
We firstly reported that Vasohibin-1 could be expressed in
gastric cancer cell lines except in the endothelium cells of
vessels, and found that Vasohibin-1 expression in cancer cells
could be regulated by TAMs [10]. However, there is little
information about the Vasohibin-1 expression in gastric can-
cer tissues and the relationship with the survivals before our
research. In this study, we found that Vasohibin-1 high expres-
sion was associated with tumor deeper depth of invasion,
lymph node metastasis, distant metastasis, and worse OS
and PFS. Kitajima and colleagues [17] found that overexpres-
sion of Vasohibin-1 in colon cancer cells increased malignant
potential and promoted metastasis. There were also reports
about high Vasohibin-1 expression presented worse tumor
clinicopathological characteristics in lung cancer [18], renal
cancer [19], hepatocellular cancer [20], and prostate cancer
[21]. Therefore, Vasohibin-1 might be a molecular marker of
Fig. 4 a The effect of Vasohibin-
1 on the length of tube forming
structures in co-culture of
endothelial cells, macrophages,
and gastric cancer cells.
Endothelial cells (EA.hy923)
were cultured alone or with
gastric cancer cells and/or with
macrophages. FBS (5 %) and
EGF (10 ng/mL) were used as
positive controls. Vasohibin-1
expression was decreased in
cancer cells with siRNA
technique. Non-targeting siRNA
was used as a control. b
Decreasing Vasohibin expression
increases the length of tube
forming structures
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worse tumor biological behavior of cancer, even if Vasohibin-
1 is an angiogenesis inhibitor. Moreover, we also found that
the expression of Vasohibin-1 expression is parallel with the
VEGF-A expression in gastric cancer tissue, which is in ac-
cordance with our previous study in the gastric cancer cells
lines. Therefore, we speculated that the anti-angiogenesis of
Vasohibin-1 might keep the balance with the pro-angiogenesis
with VEGF-A expression in the human body, which could be
explained by the results from Kimura and colleagues that the
function of endogenous Vasohibin-1 was to terminate
angiogenesis rather than to inhibit it in the sprouting front
[22]. Our study also showed that Vasohibin-1 siRNA signifi-
cantly increased the mobility of gastric cancer cell and endo-
thelium cells vessel formation in Matrigel. Hence, Vasohibin-
1 might become a new anti-angiogenesis target of gastric can-
cer in future expect for bevacizumab, which is a humanized
monoclonal antibody against angiogenesis induced by VEGF.
We firstly described the regulation of TAMs for Vasohibin-
1 expression in gastric cancer [10] and pancreatic cancer [12].
Nude mice tumorigenicity assay showed gastric cancer cells
Fig. 5 Nude mice tumor genesis assay. a Experimental nude mice with
xenograft (AGS group); b xenografts resected from the nude mice. c
Tumor volume of different test time in different groups (groups: AGS
alone and mixture of AGS and THP cells (5:1, 10:1, and 20:1)). d Tumor
weight in different groups. e Vasohibin-1 expression in different groups
under immunohistochemistry. f Vasohibin-1 immunohistochemistrical
score of different groups. g VEGF-A expression in different groups
under immunohistochemistry. h VEGF-A immunohistochemistrical
score of different groups. i MVD marked by CD34 in different groups
under immunohistochemistry. j Mean of MVD in xenografted tumor of
different groups. k Correlation between Vasohibin-1 and VEGF-A
expression in gastric xenografted tumor of nude mice. l Correlation
between Vasohibin-1 expression and MVD in gastric xenografted tumor
of nude mice
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and macrophages mixed group, especially for the ratio of
10:1, significantly had bigger volume, weight, as well as
higher Vasohibin-1, VEGF-A expression, and MVD com-
pared to the gastric cancer cells alone group. It indicated that
TAMs could promote the tumor growth and metastasis related
to angiogenesis through cytokines including anti- and pro-
angiogenesis factors. It synchronized our previous results
from cell lines that TAMs could increase the mobility of
gastric cancer cells in Matrigel and Vasohibin-1 expression
in gastric cancer cells [10].
Moreover, in this study, the length of tube forming struc-
tures of endothelial cells in vitro showed that Vasohibin-1
expression in gastric cancer cells significantly decreased the
ability of vessel formation of endothelium cells, which was
up-regulated by TAMs. Other studies had shown TAMs could
present angiostatic effects and angiogenic effects in tumors
Fig. 5 (continued)
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through cytokines including IL12,MMP12, VEGF, and so on.
Our series of studies indicated that TAMs might regulate the
angiogenesis through the Vasohibin-1, inhibition of
Vasohibin-1 could increase the effect of TAMs on the angio-
genesis. Therefore, we speculated Vasohibin-1 might not only
function as an intrinsic inhibitor of angiogenesis in the endo-
thelium cells but also play an import role in the process of
regulation by TAMs.
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